TG Therapeutics, Inc.
TGTX
$37.25
-$0.10-0.27%
| 12/31/2024 | 09/30/2024 | ||||
|---|---|---|---|---|---|
| Revenue | 28.98% | 14.17% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 28.98% | 14.17% | |||
| Cost of Revenue | 64.85% | 12.49% | |||
| Gross Profit | 24.48% | 14.39% | |||
| SG&A Expenses | -7.16% | 8.19% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 9.51% | 10.51% | |||
| Operating Income | 140.86% | 41.04% | |||
| Income Before Tax | 496.37% | -34.85% | |||
| Income Tax Expenses | 446.91% | 218.29% | |||
| Earnings from Continuing Operations | 501.31% | -43.60% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 501.31% | -43.60% | |||
| EBIT | 140.86% | 41.04% | |||
| EBITDA | 140.72% | 40.86% | |||
| EPS Basic | 501.50% | -43.79% | |||
| Normalized Basic EPS | 495.11% | -34.98% | |||
| EPS Diluted | 649.00% | -50.00% | |||
| Normalized Diluted EPS | 498.19% | -35.41% | |||
| Average Basic Shares Outstanding | 0.10% | 0.26% | |||
| Average Diluted Shares Outstanding | -0.29% | 0.81% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||
